Claudio Franceschi

EpImAge combines epigenetic and immunological markers to predict biological age with high accuracy, showing sensitivity to multiple diseases.

This study performs a meta-analysis of epigenetic age acceleration across 93 datasets and 23K samples, highlighting geographic, ethnic, and gender differences in aging rates.

The paper develops a small immunological age clock model called SImAge using 10 biomarkers, achieving high accuracy with a deep neural network.

This study examines epigenetic age acceleration and adaptation mechanisms in the Yakutian population using DNA methylation data, finding higher age acceleration and region-specific methylation patterns related to climate adaptation and aging.

The paper develops a parenclitic network approach to analyze DNA methylation changes in Down Syndrome and related cohorts, identifying network-level differences across age and health status.

This study shows CKD patients have accelerated aging linked to inflammation, using DNA methylation and protein biomarkers.

The paper presents a method for classifying healthy individuals and patients using whole blood DNA methylation data, including data harmonization, imputation, and XAI for model explanation.

The paper identifies an epigenetic signature in Cockayne syndrome fibroblasts, showing similarities to normal aging and differences from other progeroid diseases.

The paper analyzes age-dependent DNA methylation variability, identifying deterministic and stochastic CpG probes and nonlinear relationships between methylation levels and age.

This study identifies age-associated DNA methylation changes in Alzheimer's disease, showing accelerated epigenetic aging but no significant sex interaction.

The paper assesses sex-specific DNA methylation changes with aging using whole blood datasets, finding 43% of sex-associated probes show age-related methylation changes and higher methylation variability in males.

Profiling 2,925 plasma proteins in 4,331 people aged 18-95 reveals non-linear aging: protein waves crest at 34, 60 and 78 years, later waves overlapping disease proteomes.